(177)Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial

PURPOSE: Lutetium-177 prostate-specific membrane antigen-617 ((177)Lu-PSMA-617) in end-stage metastatic castration-resistant prostate cancer (mCRPC) has reported favourable outcomes. In this study, we aimed to prospectively compare the efficacy and safety of (177)Lu-PSMA-617 and docetaxel in chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Satapathy, Swayamjeet, Mittal, Bhagwant Rai, Sood, Ashwani, Das, Chandan Krushna, Mavuduru, Ravimohan Suryanarayan, Goyal, Shikha, Shukla, Jaya, Singh, Shrawan Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627907/
https://www.ncbi.nlm.nih.gov/pubmed/34842950
http://dx.doi.org/10.1007/s00259-021-05618-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627907/
https://www.ncbi.nlm.nih.gov/pubmed/34842950
http://dx.doi.org/10.1007/s00259-021-05618-3

Ejemplares similares